undamentalytics Newsletter
Sign in

Precipio, Inc. (PRPO) stock

Add to watchlist

Add holding +

NASDAQ: PRPO Nasdaq Life Sciences Tools & Services

C+ Fundamentals grade

Precipio, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$120

Revenue-to-maturity cash-flow model

Base case. Range ~$100–$150 across our lower- and higher-growth cases (24.5%–34.5% a year).

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Precipio, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling3 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
  • Funds9 adding, 6 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Precipio files

Where Precipio stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $61m, up 29.5% on a year earlier, about the same pace as a quarter earlier. That growth ranks 5 of 46 among the life sciences tools & services companies we cover. Free-cash-flow margin held at 1.3%. Operating margin widened to -2.5% from -5.6%. The diluted share count is up 13.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 6 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $125 a share, against a share price of $19.57.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Precipio, Inc.'s trailing-twelve-month revenue grew 29.5% year on year, with a free-cash-flow margin of 1.3%. Where it stands out: days sales outstanding of 14 days ranks 2 of 48 life sciences tools & services companies we cover. Where it lags: gross margin of 19.7% ranks 42 of 45 life sciences tools & services companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 26% in the quarter to 2023-09-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 29.5% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Margins widening. Operating margin is up 3.0 points on a year ago.

Things to watch

  • Loss-making. Operating margin is -2.5%: costs exceed revenue.
  • Share dilution. Diluted shares rose 13.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 61% and a beta of 0.5 against the S&P 500.
  • Below peers: gross margin. Gross margin of 19.7% ranks 42 of 45 life sciences tools & services companies we cover (median 52.0%).

Latest results: FY2026 Q2

Filed August 14, 2026
Earnings per share
-$1.04 against an average estimate of -$1.40: beat by 25.7%
Revenue
$15m, up 21.9% on a year earlier
Share reaction
+3.0% in the first session after the results on August 14, 2026, against -0.7% for the S&P 500

Precipio's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.7%
  • 1 week-8.1%
  • 1 month-23.1%
  • This year-22.6%
  • 1 year-13.2%
  • 5 years-63.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$60.8M
Operating margin
-2.5%
Net margin
-2.0%
EPS (TTM, diluted)
$-0.71

Growth

Revenue growth
+29.5%
Change in growth rate
−0.4 pts
Share count change
+13.3%

Cash

Free cash flow (TTM)
$789,000
FCF margin
1.3%
Stock pay % of revenue
3.4%

Earnings

Last results
August 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Precipio, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Precipio, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$120 ~$100–$150 Left out: out of range vs price (7.01x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$47 ~$62–$230 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$47 ~$47–$230 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Precipio, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 201720182019202020212022202320242025Now
Share price$360.00$46.20$41.00$41.40$31.60$11.02$6.50$5.54$22.98$17.79
Market value$1.0bn$40m$35m$34m$33m$13m$8m$8m$37m$31m
+ Net debt (− = net cash)$3m$4m−$305000−$2m−$11m−$3m−$1m−$1m−$3m−$3m
Enterprise value$1.0bn$44m$35m$32m$22m$9m$7m$7m$34m$28m
Multiples
Price / sales n/m13.9x4.3x2.1x3.8x0.6x0.6x0.2x0.7x0.5x
Price / earnings ——————————
Price / free cash flow ———————37.6x102.7x38.8x
EV / EBITDA ————————n/m—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Precipio's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -35.4% of total assets over 8 years.

  • Pricing power 2 / 20

    Gross margin has been a median 16.6%, moving by 8.5 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -79.4%; its worst year was -683.1%.

  • Cash conversion 3 / 20

    Free cash flow was positive in 3 of 10 years, at a median -50.4% of revenue.

  • Discipline 2 / 20

    The diluted share count rose 4159.3% over five years; stock-based pay has been a median 8.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Precipio, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2023 −$1.40 −$1.04 +25.7%
Jun 2023 −$2.00 −$1.80 +10.0%
Mar 2023 −$2.60 −$2.60 0.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
3.6%
of tradable shares
Days to cover
0.77
at average volume
Short interest, 1 month
−20%
to October 15, 2026
Held by institutions
18%
of shares
Held by insiders
12.7%
of shares
Employees
61
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −13.2%

$20.50 on October 31, 2025 to $17.79

ThenNowEffect
Revenue (last 12 months) $47m $61m +29.5%
P/S multiple 0.7x 0.5x −24.1%
Share count 2m 2m −11.7%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +110.0%

$8.47 on November 3, 2023 to $17.79

ThenNowEffect
Revenue (last 12 months) $21m $61m +196.2%
P/S multiple 0.5x 0.5x +4.9%
Share count 1m 2m −32.4%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
PRPO−24%−65%−41%−15%+315%−23%
Industry peers (median)+5%−51%−3%−13%−7%+16%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
PRPO33%33%17%42%75%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
PRPO−70%−71%−74%−36%−56%−45%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since June 30, 2017: 100% from July 5, 2017 to July 16, 2024. Getting back needed a 135711% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$17.79 – $32.37
From 52-week high
−45.0%
vs 50-day average
−26.9%
vs 200-day average
−28.7%
Volatility (1 year)
61%
Beta vs S&P 500
0.47

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±8.6%
After a week
7 up, 5 down
typical move ±13.5%
After a month
6 up, 6 down
typical move ±23.9%
Results releasedNext dayS&P 500 next day5 days21 days
August 14, 2026 +3.0% −0.7% +31.2% +17.0%
February 27, 2026 +1.6% −0.4% +9.2% −1.6%
May 15, 2025 +13.6% +1.1% +40.6% +57.0%
February 28, 2022 −3.9% −1.8% −3.9% −12.9%
July 28, 2021 +4.1% +0.4% +1.4% +23.9%
July 22, 2020 −18.8% −0.6% −23.1% +70.0%
February 14, 2019 +4.7% +0.9% 0.0% −10.6%
October 16, 2018 +8.6% +2.2% −5.4% −2.9%
July 18, 2018 +13.5% −0.2% +1.4% +18.6%
May 14, 2018 +11.1% −0.6% +10.5% +27.6%
February 9, 2018 −17.5% +3.0% −31.2% −39.8%
November 21, 2017 −2.6% +0.6% +4.7% −5.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Precipio, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Precipio, Inc.
$0 $20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $25.3M Revenue (TTM), FY23 Q4: $12.5M Revenue (TTM), FY24 Q1: $17.4M Revenue (TTM), FY24 Q2: $20M Revenue (TTM), FY24 Q3: $22.3M Revenue (TTM), FY24 Q4: $41.8M Revenue (TTM), FY25 Q1: $44.8M Revenue (TTM), FY25 Q2: $47M Revenue (TTM), FY25 Q3: $50.3M Revenue (TTM), FY25 Q4: $53.5M Revenue (TTM), FY26 Q1: $58.1M Revenue (TTM), FY26 Q2: $60.8M $60.8M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $25.3M
FY23 Q4 $12.5M
FY24 Q1 $17.4M
FY24 Q2 $20M
FY24 Q3 $22.3M
FY24 Q4 $41.8M
FY25 Q1 $44.8M
FY25 Q2 $47M
FY25 Q3 $50.3M
FY25 Q4 $53.5M
FY26 Q1 $58.1M
FY26 Q2 $60.8M
Revenue growth, TTM YoY Precipio, Inc.
-100% 0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 144.8% Revenue growth, TTM YoY, FY23 Q4: -38.6% Revenue growth, TTM YoY, FY24 Q1: -4.3% Revenue growth, TTM YoY, FY24 Q2: -2.8% Revenue growth, TTM YoY, FY24 Q3: -11.7% Revenue growth, TTM YoY, FY24 Q4: 235.6% Revenue growth, TTM YoY, FY25 Q1: 157.7% Revenue growth, TTM YoY, FY25 Q2: 135.3% Revenue growth, TTM YoY, FY25 Q3: 125.1% Revenue growth, TTM YoY, FY25 Q4: 28.0% Revenue growth, TTM YoY, FY26 Q1: 29.9% Revenue growth, TTM YoY, FY26 Q2: 29.5% 29.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 144.8%
FY23 Q4 -38.6%
FY24 Q1 -4.3%
FY24 Q2 -2.8%
FY24 Q3 -11.7%
FY24 Q4 235.6%
FY25 Q1 157.7%
FY25 Q2 135.3%
FY25 Q3 125.1%
FY25 Q4 28.0%
FY26 Q1 29.9%
FY26 Q2 29.5%
Operating margin (TTM) Precipio, Inc.
-80% -60% -40% -20% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -36.0% Operating margin (TTM), FY23 Q4: -61.2% Operating margin (TTM), FY24 Q1: -38.4% Operating margin (TTM), FY24 Q2: -28.0% Operating margin (TTM), FY24 Q3: -21.2% Operating margin (TTM), FY24 Q4: -10.1% Operating margin (TTM), FY25 Q1: -6.7% Operating margin (TTM), FY25 Q2: -5.6% Operating margin (TTM), FY25 Q3: -4.1% Operating margin (TTM), FY25 Q4: -2.2% Operating margin (TTM), FY26 Q1: -3.0% Operating margin (TTM), FY26 Q2: -2.5% -2.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -36.0%
FY23 Q4 -61.2%
FY24 Q1 -38.4%
FY24 Q2 -28.0%
FY24 Q3 -21.2%
FY24 Q4 -10.1%
FY25 Q1 -6.7%
FY25 Q2 -5.6%
FY25 Q3 -4.1%
FY25 Q4 -2.2%
FY26 Q1 -3.0%
FY26 Q2 -2.5%
FCF margin (TTM) Precipio, Inc.
-100% -50% 0% 50% FY22 Q2 FY23 Q1 FY23 Q4 FY26 Q2 FCF margin (TTM), FY22 Q2: -79.7% FCF margin (TTM), FY22 Q3: -76.9% FCF margin (TTM), FY22 Q4: -39.4% FCF margin (TTM), FY23 Q1: -39.9% FCF margin (TTM), FY23 Q2: -32.8% FCF margin (TTM), FY23 Q3: -21.0% FCF margin (TTM), FY23 Q4: -29.6% FCF margin (TTM), FY25 Q2: 1.2% FCF margin (TTM), FY25 Q3: 1.2% FCF margin (TTM), FY25 Q4: 0.7% FCF margin (TTM), FY26 Q1: 1.0% FCF margin (TTM), FY26 Q2: 1.3% 1.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q2 -79.7%
FY22 Q3 -76.9%
FY22 Q4 -39.4%
FY23 Q1 -39.9%
FY23 Q2 -32.8%
FY23 Q3 -21.0%
FY23 Q4 -29.6%
FY25 Q2 1.2%
FY25 Q3 1.2%
FY25 Q4 0.7%
FY26 Q1 1.0%
FY26 Q2 1.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 22 20 32 31 28 1 2 2 2 3 8 16 9 20 15 42 53 61
Gross profit 12 10 18 13 11 −1 −0 1 0 0 0 1 2 3 6 8 11 12
EBITDA −1 −3 −1 −7 −13 −10 −8 −2 −15 −13 −10 −8 −8 −12 −6 −3 0 −0
Operating income −2 −4 −3 −10 −16 −11 −9 −2 −16 −14 −11 −9 −10 −13 −8 −4 −1 −2
Net income −2 −3 −10 −8 −16 −14 −33 −2 −21 −16 −13 −14 −9 −12 −6 −4 −0 −1
Diluted EPS −$0.00 −$0.10 −$4.37 −$2.58 −$0.19 −$0.17 −$0.23 −$15.73 −$11.93 −$23.03 −$0.78 −$17.00 −$0.40 −$10.73 −$4.51 −$2.93 −$0.23 −$0.71
Growth (year on year)
Revenue — −9.0% +59.5% −1.5% −12.5% −95.5% +55.6% −10.7% 0.0% +66.2% +185.4% +94.3% −44.3% +129.3% −25.1% +174.9% +28.0% +29.5%
Margins
Gross margin 52.7% 48.7% 57.7% 41.7% 39.0% −75.4% −0.6% 43.7% 16.9% 7.9% 2.7% 7.2% 27.0% 12.4% 39.6% 18.1% 20.0% 19.7%
EBITDA margin −4.7% −14.5% −2.7% −23.0% −47.2% −806.5% −437.0% −92.9% −857.1% −441.6% −120.8% −50.7% −95.9% −57.1% −42.1% −7.2% 0.1% −0.6%
Operating margin −8.6% −18.0% −9.3% −30.2% −57.2% −852.3% −462.4% −99.4% −900.2% −485.8% −134.5% −57.6% −108.6% −63.1% −50.1% −10.1% −2.2% −2.5%
Net margin −8.7% −15.6% −30.6% −26.5% −58.0% <−999% <−999% −129.3% <−999% −548.0% −162.0% −87.9% −96.4% −60.1% −38.5% −10.3% −0.7% −2.0%
Free-cash-flow margin 4.2% −9.5% −0.0% −35.2% −33.0% <−999% −652.3% −56.8% −396.6% −239.2% −112.5% −47.8% −82.0% −39.4% −24.2% 0.5% 0.7% 1.3%
Cash flow
Cash from operations 1 −2 0 −10 −8 −14 −12 −1 −7 −7 −9 −7 −7 −8 −4 0 1 1
Capital spending 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 0 0
Free cash flow 1 −2 −0 −11 −9 −14 −13 −1 −7 −7 −9 −8 −7 −8 −4 0 0 1
Stock-based pay 0 −0 1 1 0 1 1 0 0 1 1 1 2 4 2 1 1 2
Free cash flow after stock pay 1 −2 −1 −12 −10 −15 −13 −1 −7 −7 −10 −8 −9 −12 −5 −1 −1 −1
Balance sheet
Cash 6 3 5 4 2 2 0 0 0 0 1 3 12 3 2 1 3 3
Total debt 0 10 12 6 7 8 8 5 3 5 1 1 0 0 0 0 0 0
Net debt (negative = net cash) −6 6 7 2 5 6 7 5 3 4 −0 −2 −11 −3 −1 −1 −3 −3
Diluted shares — 30m 2m 3m 4m 4m 7m 260m 3m — — — 1m 1m 1m 1m 2m 2m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $21m
Short-term assets $7mLonger-term assets $15m
What it owes, and who funded it · $21m
Short-term liabilities $4mLonger-term liabilities $3mShareholders' equity $15m
  • Short-term assets cover short-term liabilities $7m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $7m short-term assets against $3m of longer-dated liabilities.
  • More cash than debt $3m of cash against $325,000 of debt.
  • Debt below 40% of shareholders' equity Debt is 2% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 1% to 2% over five years.
  • A year's operating cash flow covers at least 20% of debt $1m of operating cash flow against $325,000 of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Precipio, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+13.3%
year over year
Days sales outstanding
14 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated PRPO MASS CSBR PSNL XGN BNR Median
Revenue, last 12 months $61m $61m $61m $70m $71m $75m $229m
Revenue growth, last 12 months 29.5% 13.4% 6.7% −13.3% 20.8% 4.7% 6.9%
Revenue growth, 3-year average 43.6% 7.5% 4.8% 1.2% 10.3% — 2.9%
Revenue growth, latest quarter 21.9% 23.3% 8.8% 30.0% 15.9% — 8.5%
Gross margin 19.7% 52.2% 49.8% 12.7% 58.6% 74.7% 51.9%
Operating margin −2.5% −64.0% −1.7% −164.1% −18.6% −10.2% −14.3%
Operating margin, 3-year average −12.0% −87.7% −1.2% −122.3% −23.4% — −22.4%
Net margin −2.0% −57.0% −1.8% −153.8% −26.6% −10.3% −16.1%
Cash from operations / revenue 1.8% 2.5% −9.2% −132.5% −9.1% −5.3% 1.3%
Free-cash-flow margin 1.3% 1.0% −10.1% −144.9% −10.7% −6.2% −2.2%
Free-cash-flow margin, 3-year average −12.5% −38.7% −0.4% −96.1% −16.3% — 0.6%
Stock pay / revenue 3.4% 16.2% 3.0% 15.7% 4.1% 2.6% 4.4%
Change in share count 13.3% 4.3% −2.4% 26.0% 23.9% −100.0% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 29.5% 6.9% 6 of 54
Change in growth rate Growth -0.4pp +0.4pp 33 of 54
Gross margin Profitability 19.7% 52.0% 42 of 45
Operating margin Profitability -2.5% -14.3% 21 of 52
Net margin Profitability -2.0% -12.2% 19 of 54
Free-cash-flow margin Cash generation 1.3% -1.3% 24 of 54
Stock pay as % of revenue Cash generation 3.4% 4.4% 23 of 53
Long-term debt as % of assets Balance sheet 1.2% 26.3% 6 of 35
Change in share count Balance sheet 13.3% 1.0% 38 of 46
Days sales outstanding Balance sheet 14 days 62 days 2 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Service Revenue Net $21.5M ▲ 34.7%
Products $2.7M ▲ 4.9%

These categories overlap or exclude eliminations, so shares aren't shown.

From Precipio, Inc.'s 10-K filed March 30, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$3.9M
Institutions reporting
17
Shares held vs prior quarter
▲ 4.3%
Positions opened / closed
5 / 2

Top buyers and sellers, Q2 2026: 9 institutions bought and 6 sold ; the biggest buyer was Vanguard Capital Management LLC (+21K shares) and the biggest seller Topline Capital Management, LLC (−25K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $1.1M 46K 29.2% ▲ 81.1%
Blackrock, Inc. $858,058 35K 21.9% ▲ 19.4%
Geode Capital Management, LLC $462,912 19K 11.8% ▼ 0.6%
Renaissance Technologies LLC $401,087 16K 10.2% ▼ 16.1%
Citadel Advisors LLC $364,319 15K 9.3% ▼ 2.7%
Xtx Topco Ltd $233,982 9K 6.0% New
Vanguard Fiduciary Trust Co $232,917 9K 5.9% ▲ 0.7%
Dimensional Fund Advisors LP $207,885 8K 5.3% New
UBS Group AG $8,493 0K 0.2% ▲ 51.1%
Wells Fargo & Company $1,238 0K 0.0% 0.0%
Tower Research Capital LLC (TRC) $792 0K 0.0% ▼ 76.8%
Morgan Stanley $173 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Precipio, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $1,467 3 trades by 1 insider, last 12 months Insider sales History → $100,296 4 trades by 1 insider · 0% under pre-set plans
Net ▼ $98,829 net selling
Insider Date Trade Shares Price Value
Sandberg Richard A Director May 21, 2026 Sell 900 $25.02 $22,518
Sandberg Richard A Director May 20, 2026 Sell 500 $25.00 $12,500
Sandberg Richard A Director May 20, 2026 Sell 2,034 $24.89 $50,626
Sandberg Richard A Director May 19, 2026 Sell 600 $24.42 $14,652
Sabet Ahmed Zaki Chief Operating Officer April 1, 2026 Buy pre-set plan 19 $27.93 $531
Sabet Ahmed Zaki Chief Operating Officer January 2, 2026 Buy pre-set plan 20 $23.40 $468
Sabet Ahmed Zaki Chief Operating Officer January 2, 2026 Buy pre-set plan 20 $23.40 $468

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • August 14, 2026
  • February 27, 2026
  • May 15, 2025
  • February 28, 2022
  • July 28, 2021
  • July 22, 2020

Recent SEC filings

Data status

When each part of this page on Precipio, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Precipio, Inc. in brief

What does Precipio, Inc. do?
Precipio, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Precipio, Inc.'s stock ticker?
Precipio, Inc. trades under the ticker PRPO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Precipio, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Precipio, Inc. reported revenue of $60.8M, 29.5% higher than a year earlier, according to its SEC filings.
What is Precipio, Inc.'s free cash flow?
Precipio, Inc.'s free-cash-flow margin is 1.3% of revenue over the trailing twelve months, ranking 24 of the 54 life sciences tools & services companies we cover.
Who are Precipio, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Blackrock, Inc. and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Precipio, Inc.'s market cap?
On November 2, 2026, Precipio, Inc.'s market capitalisation was about $30.6M and net debt of -$2.8M. Market figures come from third-party market data and may be delayed.
How much debt does Precipio, Inc. have?
Precipio, Inc.'s debt-to-equity ratio is 2.2%, from its latest balance sheet (0.7% five years earlier). The financial health section below sets out its other solvency checks.
Who are Precipio, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Precipio, Inc. are 908 Devices Inc., Champions Oncology, Inc., Personalis, Inc., Exagen Inc. and Burning Rock Biotech Ltd. The side-by-side comparison below sets their revenue, margins and growth against Precipio, Inc.'s.
Are insiders buying or selling Precipio, Inc. stock?
Over the last 12 months, Precipio, Inc.'s directors and officers reported 3 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.